CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (USD $) In Millions, unless otherwise specified	Sep. 30, 2012		Dec. 31, 2011
Assets
Cash and cash equivalents	$ 4,506		$ 3,182
Short-term investments	18,462		23,270
Accounts receivable, less allowance for doubtful accounts	12,523		13,058
Inventories	7,516		6,610
Taxes and other current assets	8,849		9,380
Assets of discontinued operations and other assets held for sale	5,271		5,317
Total current assets	57,127		60,817
Long-term investments	13,429		9,814
Property, plant and equipment, less accumulated depreciation	14,606		15,921
Goodwill	44,370		44,569
Identifiable intangible assets, less accumulated amortization	47,209	[1]	51,184	[1]
Taxes and other noncurrent assets	5,862		5,697
Total assets	182,603		188,002
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt	7,774	[2],[3]	4,016	[2],[3]
Accounts payable	2,967		3,678
Dividends payable	1		1,796
Income taxes payable	1,788		1,009
Accrued compensation and related items	1,736		2,120
Other current liabilities	13,455		15,066
Liabilities of discontinued operations	1,410		1,224
Total current liabilities	29,131		28,909
Long-term debt	31,083	[2],[4],[5]	34,926	[2],[4],[5]
Pension benefit obligations	6,560		6,341
Postretirement benefit obligations	3,309		3,344
Noncurrent deferred tax liabilities	19,133		18,861
Other taxes payable	6,011		6,886
Other noncurrent liabilities	5,261		6,114
Total liabilities	100,488		105,381
Commitments and Contingencies
Preferred stock	41		45
Common stock	447		445
Additional paid-in capital	72,317		71,423
Employee benefit trusts	(2)		(3)
Treasury stock	(36,703)		(31,801)
Retained earnings	51,256		46,210
Accumulated other comprehensive loss	(5,653)		(4,129)
Total Pfizer Inc. shareholders' equity	81,703		82,190
Equity attributable to noncontrolling interests	412		431
Total equity	82,115		82,621
Total liabilities and equity	$ 182,603		$ 188,002

[1] The decrease is primarily related to amortization, as well as impairment charges (see Note 4. Other Deductions—Net), partially offset by the assets acquired as part of the acquisitions of Ferrosan and Alacer (see Note 2A. Acquisitions and Divestitures: Acquisitions).

[2] Some carrying amounts may include adjustments for discount or premium amortization or for the effect of interest rate swaps designated as hedges.

[3] The differences between the estimated fair values and carrying values of these financial assets and liabilities not measured at fair value on a recurring basis were not significant as of September 30, 2012 or December 31, 2011. Held-to-maturity debt securities and our short-term and long-term debt fair value are based on Level 2 valuations using a market approach. Fair value measurements for private equity securities carried at cost are based on Level 3 valuations using a market approach.

[4] Includes foreign currency debt with fair values of $898 million as of September 30, 2012 and $919 million as of December 31, 2011, which are used as hedging instruments.

[5] The fair value of our long-term debt (not including the current portion of long term debt) is $36.5 billion as of September 30, 2012 and $40.1 billion as of December 31, 2011.